EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY

被引：0

作者：

Wedemeyer, Heiner ^{[1
]}

Aleman, Soo ^{[2
]}

Brunetto, Maurizia ^{[3
]}

Blank, Antje ^{[4
]}

Andreone, Pietro ^{[5
]}

Bogomolov, Pavel ^{[6
]}

Chulanov, Vladimir ^{[7
]}

Mamonova, Nina ^{[7
]}

Geyvandova, Natalia ^{[8
]}

Morozov, Viacheslav ^{[9
]}

Sagalova, Olga ^{[10
]}

Stepanova, Tatyana ^{[11
]}

Manuilov, Dmitry ^{[12
]}

Mercier, Renee-Claude ^{[12
]}

An, Qi ^{[12
]}

Flaherty, John ^{[12
]}

Osinusi, Anu ^{[12
]}

Lau, Audrey ^{[12
]}

zur Wiesch, Julian Schulze ^{[13
]}

Cornberg, Markus ^{[1
]}

Zeuzem, Stefan ^{[14
]}

Lampertico, Pietro ^{[15
,16
]}

机构：

[1] Hannover Med Sch, Klin Gastroenterol Hepatol & Endokrinol, Hannover, Germany

[2] Karolinska Inst, Dept Infect Dis, Karolinska Univ Hosp, Stockholm, Sweden

[3] Univ Pisa, Univ Hosp Pisa, Dept Clin & Expt Med, Hepatol Unit,Reference Ctr Tuscany Reg Chron Live, Pisa, Italy

[4] Heidelberg Univ Hosp, Clin Pharmacol & Pharmacoepidemiol, Heidelberg, Germany

[5] Univ Modena & Reggio Emilia, Baggiovara Hosp, Internal Med, Reggio Emilia, Italy

[6] Moscow Reg Res Clin Inst, State Budgetary Inst Hlth Care Moscow Reg, Moscow, Russia

[7] Minist Hlth Russian Federat, FSBI Natl Res Med Ctr Phthisiopulmonol & Infect D, Moscow, Russia

[8] Stavropol Reg Hosp, Stavropol, Russia

[9] LLC Med Co Hepatolog, Samara, Russia

[10] Southern Ural State Madical Univ, Minist Hlth Russian Federat, Fed State Funded Inst Higher Educ, Chelyabinsk, Russia

[11] Ltd Liabil Co, Clin Modern Med, Moscow, Russia

[12] Gilead Sci, Foster City, CA USA

[13] Univ Klinikum Hamburg Eppendorf, Med Klin Studienambulanz Hepatol, Hamburg, Germany

[14] Univ Hosp Frankfurt, Dept Med, Frankfurt, Germany

[15] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy

[16] Univ Milan, CRC AM & A Migliavacca Ctr Liver Dis, Dept Pathophysiol & Transplantat, Milan, Italy

来源：

GUT | 2023年 / 72卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P134

引用

页码：A103 / A104

页数：2

共 50 条

[1] Efficacy and safety of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis delta at 96 weeks: Results from an interim analysis of a phase 3 randomized study
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Freismuth, Aurelie
Flaherty, John F.
Osinusi, Anu
Lau, Audrey
Wiesch, Julian Schulze Zur
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 101 - 102
[2] EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Flaherty, John
Osinusi, Anu
Lau, Audrey
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
GUT, 2023, 72 (SUPPL_3) : A103 - A104
[3] EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia R.
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana V.
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Flaherty, John F.
Osinusi, Anu
Lau, Audrey H.
Wiesch, Julian Schulze zur
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
GASTROENTEROLOGY, 2024, 166 (05) : S1600 - S1600
[4] Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Viacheslav, Morozov
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Flaherty, John F.
Osinusi, Anu
Lau, Audrey
Wiesch, Julian Schulze Zur
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
JOURNAL OF HEPATOLOGY, 2023, 78 : S57 - S58
[5] Efficacy and Safety of Bulevirtide Monotherapy for Chronic Hepatitis Delta in Patients With and Without Cirrhosis: Results From the Week 96 Interim Analysis of a Phase 3 Randomized Study
Aleman, Soo
Wedemeyer, Heiner
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Da, Ben
Flaherty, John F.
Buensuceso, Paul
Osinusi, Anu
Lau, Audrey H.
Christian-Cox, Florence
Tseng, Steve
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1384 - S1385
[6] Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing phase 3 study, MYR301
Lampertico, Pietro
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Chee, Grace M.
Manuilov, Dmitry
Li, Mingyang
Tseng, Steve
Lau, Audrey
Osinusi, Anu
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Wedemeyer, Heiner
JOURNAL OF HEPATOLOGY, 2024, 80 : S92 - S92
[7] HIGH RATES OF ADHERENCE TO BULEVIRTIDE MONOTHERAPY FOR CHRONIC HEPATITIS DELTA THROUGH 96 WEEKS: RESULTS FROM AN INTERIM ANALYSIS OF THE PHASE 3 STUDY MYR301
Aleman, Soo
Wedemeyer, Heiner
Brunetto, Maurizia R.
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana V.
Da, Ben
Manuilov, Dmitry
Chee, Grace
Li, Mingyang
Lau, Audrey H.
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
GASTROENTEROLOGY, 2024, 166 (05) : S1603 - S1604
[8] EFFICACY AND SAFETY OF BULEVIRTIDE MONOTHERAPY GIVEN AT 2 MG OR 10 MG DOSE LEVEL ONCE DAILY FOR TREATMENT OF CHRONIC HEPATITIS DELTA: WEEK 48 PRIMARY ENDPOINT RESULTS FROM A PHASE 3 RANDOMIZED, MULTICENTER, PARALLEL-DESIGN STUDY
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia R.
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana V.
Manuilov, Dmitry
Shah, Vicki
Suri, Vithika
An, Qi
Flaherty, John F.
Osinusi, Anu
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
GASTROENTEROLOGY, 2023, 164 (06) : S1367 - S1368
[9] Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Viacheslav, Morozov
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Suri, Vithika
An, Qi
Flaherty, John F.
Osinusi, Anu
Zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
JOURNAL OF HEPATOLOGY, 2022, 77 : S4 - S5
[10] Safety and efficacy of up to 76 weeks 10 mg/day (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis
Loglio, A.
Ferenci, P.
Schlund, F.
Tham, C. Y. L.
van Bommel, F.
Renteria, S. C. Uceda
Borghi, M.
Holzmann, H.
Perbellini, R.
Trombetta, E.
Giovanelli, S.
Porretti, L.
Prati, D.
Ceriotti, F.
Lunghi, G.
Bertoletti, A.
Urban, S.
Lampertico, P.
DIGESTIVE AND LIVER DISEASE, 2020, 52 : E28 - E29

← 1 2 3 4 5 →